{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:37:21Z","timestamp":1787614641985,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: Concentrations of human tissue kallikreins (hKs), a group of 15 secreted serine proteases found in many tissues, are modulated by steroid hormones in cancer cell lines. To gain insight into in vivo kallikrein regulation we measured kallikrein concentrations in serum and urinary tissue in female-to-male transsexuals before and after testosterone administration.<\/jats:p><jats:p>Methods: We collected blood and urine samples before treatment and after 4 and 12 months from 28 female-to-male transsexuals who received 250 mg of testosterone esters intramuscularly every 2 weeks. We used ELISA assays to measure multiple kallikreins in serum and urine.<\/jats:p><jats:p>Results: After testosterone administration, serum testosterone concentrations increased by \u223c15-fold. Serum kallikrein concentrations increased dramatically for hK3 (prostate-specific antigen) and increased moderately for hK2, hK5, hK6, hK7, hK8, hK10, and hK11. In urine, we noted major increases for hK3 and hK2 only. For all other kallikrein concentrations, we observed no considerable changes.<\/jats:p><jats:p>Conclusions: We conclude that, in serum and urine of female-to-male transsexuals after testosterone administration, hK3 (prostate-specific antigen) and to a lesser extent hK2 concentrations increase dramatically, but concentration of other kallikreins increase either moderately in serum (hK5, hK6, hK7, hK8, hK10, and hK11) or not at all in either serum (hK4, hK13, hK14) or urine (hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13, hK14).<\/jats:p>","DOI":"10.1373\/clinchem.2006.067041","type":"journal-article","created":{"date-parts":[[2006,6,16]],"date-time":"2006-06-16T00:46:20Z","timestamp":1150418780000},"page":"1546-1551","source":"Crossref","is-referenced-by-count":14,"title":["Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals"],"prefix":"10.1093","volume":"52","author":[{"given":"Margrita H","family":"Slagter","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Vrije Universiteit University Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Scorilas","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis JG","family":"Gooren","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Vrije Universiteit University Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"de Ronde","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Vrije Universiteit University Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoninus","family":"Soosaipillai","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J","family":"Giltay","sequence":"first","affiliation":[{"name":"Geestelijke Gezondheidszorg Delfland, Institute of Mental Health, Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiadis","family":"Paliouras","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P","family":"Diamandis","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,8,1]]},"reference":[{"key":"2020022801251483800_R1","doi-asserted-by":"crossref","unstructured":"Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev2001;22:184-204.","DOI":"10.1210\/er.22.2.184"},{"key":"2020022801251483800_R2","doi-asserted-by":"crossref","unstructured":"Yousef GM, Diamandis EP. Expanded human tissue kallikrein family: a novel panel of cancer biomarkers. Tumour Biol2002;23:185-192.","DOI":"10.1159\/000064027"},{"key":"2020022801251483800_R3","doi-asserted-by":"crossref","unstructured":"Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett2005;224:1-22.","DOI":"10.1016\/j.canlet.2004.09.024"},{"key":"2020022801251483800_R4","doi-asserted-by":"crossref","unstructured":"Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer2004;4:876-890.","DOI":"10.1038\/nrc1474"},{"key":"2020022801251483800_R5","doi-asserted-by":"crossref","unstructured":"Yousef GM, Diamandis EP. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem2002;48:1198-1205.","DOI":"10.1093\/clinchem\/48.8.1198"},{"key":"2020022801251483800_R6","doi-asserted-by":"crossref","unstructured":"Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJG, Yu H, et al. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. Clin Chem2000;46:859-862.","DOI":"10.1093\/clinchem\/46.6.859"},{"key":"2020022801251483800_R7","doi-asserted-by":"crossref","unstructured":"Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, et al. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by anti-androgens in male-to-female transsexuals. J Urol2000;163:802-805.","DOI":"10.1016\/S0022-5347(05)67808-1"},{"key":"2020022801251483800_R8","doi-asserted-by":"crossref","unstructured":"Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP. Development of ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem1999;45:790-799.","DOI":"10.1093\/clinchem\/45.6.790"},{"key":"2020022801251483800_R9","doi-asserted-by":"crossref","unstructured":"Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem1996;42:675-684.","DOI":"10.1093\/clinchem\/42.5.675"},{"key":"2020022801251483800_R10","doi-asserted-by":"crossref","unstructured":"Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunoflurometry and immunohistochemistry. Clin Chem2002;48:1232-1240.","DOI":"10.1093\/clinchem\/48.8.1232"},{"key":"2020022801251483800_R11","unstructured":"Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res2003;63:3958-3965."},{"key":"2020022801251483800_R12","doi-asserted-by":"crossref","unstructured":"Diamandis EP, Scorials A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol2003;21:1035-1043.","DOI":"10.1200\/JCO.2003.02.022"},{"key":"2020022801251483800_R13","doi-asserted-by":"crossref","unstructured":"Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, Diamandis EP. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem2004;50:709-716.","DOI":"10.1373\/clinchem.2003.029538"},{"key":"2020022801251483800_R14","doi-asserted-by":"crossref","unstructured":"Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, Diamandis EP. Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem2003;49:87-96.","DOI":"10.1373\/49.1.87"},{"key":"2020022801251483800_R15","doi-asserted-by":"crossref","unstructured":"Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem2001;47:237-246.","DOI":"10.1093\/clinchem\/47.2.237"},{"key":"2020022801251483800_R16","unstructured":"Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res2002;62:295-300."},{"key":"2020022801251483800_R17","doi-asserted-by":"crossref","unstructured":"Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem2003;49:77-86.","DOI":"10.1373\/49.1.77"},{"key":"2020022801251483800_R18","unstructured":"Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res2003;63:9032-9041."},{"key":"2020022801251483800_R19","doi-asserted-by":"crossref","unstructured":"Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab2000;85:81-84.","DOI":"10.1210\/jc.85.1.81"},{"key":"2020022801251483800_R20","doi-asserted-by":"crossref","unstructured":"Bahceci M, Bilge M, Tuzcu A, Tuzcu S, Bahceci S. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel\/ethinyl estradiol combination. J Endocrinol Invest2004;27:353-356.","DOI":"10.1007\/BF03351061"},{"key":"2020022801251483800_R21","unstructured":"Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc1999;151:209-213."},{"key":"2020022801251483800_R22","doi-asserted-by":"crossref","unstructured":"Escobar-Morreale HF, Serrano-Gotarredona J, Avila S, Villar-Palasi J, Varela C, Sancho J. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab1998;83:2580-2584.","DOI":"10.1210\/jcem.83.7.4960"},{"key":"2020022801251483800_R23","doi-asserted-by":"crossref","unstructured":"Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab1997;82:777-780.","DOI":"10.1210\/jcem.82.3.3792"},{"key":"2020022801251483800_R24","doi-asserted-by":"crossref","unstructured":"Gullu S, Emral R, Asik M, Cesur M, Tonyukuk V. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Invest2003;26:1198-1202.","DOI":"10.1007\/BF03349157"},{"key":"2020022801251483800_R25","doi-asserted-by":"crossref","unstructured":"Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem2004;93:233-241.","DOI":"10.1002\/jcb.20228"},{"key":"2020022801251483800_R26","doi-asserted-by":"crossref","unstructured":"Goh VH. Breast tissues in transsexual women-a nonprostatic source of androgen up-regulated production of prostate-specific antigen. J Clin Endocrinol Metab1999;84:313-315.","DOI":"10.1210\/jc.84.9.3313"},{"key":"2020022801251483800_R27","unstructured":"Yu H. Clinical implications of prostate-specific antigen in men and women. J Gend Specif Med2000;53:45-48."},{"key":"2020022801251483800_R28","doi-asserted-by":"crossref","unstructured":"Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int J Cancer2004;108:588-591.","DOI":"10.1002\/ijc.11607"},{"key":"2020022801251483800_R29","unstructured":"Seliger E, Kaltwasser P, Ropke F. Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium: new diagnostic approaches. Zentralbl Gynakol1998;120:72-75[German].."},{"key":"2020022801251483800_R30","unstructured":"Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, et al. Expression of human prostate-specific glandular kallikrein protein (hK2) expression in the breast cancer cell line T47-D. Cancer Res1997;57:2651-2656."},{"key":"2020022801251483800_R31","doi-asserted-by":"crossref","unstructured":"Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat2000;59:1-14.","DOI":"10.1023\/A:1006380306781"},{"key":"2020022801251483800_R32","doi-asserted-by":"crossref","unstructured":"Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology1997;49:857-862.","DOI":"10.1016\/S0090-4295(97)00108-8"},{"key":"2020022801251483800_R33","doi-asserted-by":"crossref","unstructured":"Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab2000;11:54-60.","DOI":"10.1016\/S1043-2760(99)00225-8"},{"key":"2020022801251483800_R34","doi-asserted-by":"crossref","unstructured":"Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl1999;20:348-355.","DOI":"10.1002\/j.1939-4640.1999.tb02528.x"},{"key":"2020022801251483800_R35","doi-asserted-by":"crossref","unstructured":"Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer1997;75:579-588.","DOI":"10.1038\/bjc.1997.101"},{"key":"2020022801251483800_R36","doi-asserted-by":"crossref","unstructured":"Katsaros D, Melegos DN, Diamandis EP. Prostate specific antigen production by breast tumors after induction with oral contraceptives. Clin Biochem1998;31:285-288.","DOI":"10.1016\/S0009-9120(97)00171-9"},{"key":"2020022801251483800_R37","doi-asserted-by":"crossref","unstructured":"Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer1999;85:891-898.","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<891::AID-CNCR17>3.0.CO;2-K"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/8\/1546\/32685771\/clinchem1546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/52\/8\/1546\/32685771\/clinchem1546.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T21:27:58Z","timestamp":1707082078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/52\/8\/1546\/5626891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,8,1]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2006.067041","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,8,1]]},"published":{"date-parts":[[2006,8,1]]}}}